Ann: Quarterly Activities Report and Appendix 4C, page-5

Thats interesting because last quarterly we had cash on hand of $4.385 million, this quarterly after raising $4.398 (with cap raise and SPP) 6% (263k) goes to Xcel and Sanlam, which leaves net proceeds around $4.135 million.

So cash should be approx 4.135 + 4.385 = $8.52 mill.
-$1 mill (murray meds)
=$7.52

Yet we only have 6, so 1,5 mill was used this quarter (operating was 523k, investing activities 562 - this includes a 200k loan, I guess this was given to Murray Meds) I havent included Murray Meds payment as this was already taken out above. So still 500k not really accounted for.

Anyway dont want to harp on the negative aspects, overall not really a bad quarterly and not really a good one, kind of business as usual. Like you said none of the medical marijuana aspects have shown up in this apart from the costs, so next quarterly should be showing some of the gains of those businesses.

Cannabis ETFs were up last night, seem to be bouncing off a support level, and the big players are reporting in a couple of months, so maybe we will be waiting until then and next quarterly to get some solid movement up.